Verona Pharma Plc ADR (VRNA) EPS is poised to hit -0.06 next quarter: How Investors Can Make It Count the Most?

As on Thursday, Verona Pharma Plc ADR (NASDAQ: VRNA) started slowly as it slid -1.78% to $27.03, before settling in for the price of $27.52 at the close. Taking a more long-term approach, VRNA posted a 52-week range of $11.39-$28.83.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -39.77%. Meanwhile, its Annual Earning per share during the time was 19.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -188.89%. This publicly-traded company’s shares outstanding now amounts to $80.44 million, simultaneously with a float of $62.75 million. The organization now has a market capitalization sitting at $2.19 billion. At the time of writing, stock’s 50-day Moving Average stood at $22.54, while the 200-day Moving Average is $17.55.

Verona Pharma Plc ADR (VRNA) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Verona Pharma Plc ADR’s current insider ownership accounts for 22.61%, in contrast to 62.20% institutional ownership. According to the most recent insider trade that took place on Aug 13 ’24, this organization’s President and CEO sold 398,400 shares at the rate of 3.20, making the entire transaction reach 1,275,681 in total value, affecting insider ownership by 15,850,704. Preceding that transaction, on Aug 12 ’24, Company’s President and CEO sold 1,600 for 3.13, making the whole transaction’s value amount to 5,008. This particular insider is now the holder of 16,249,104 in total.

Verona Pharma Plc ADR (VRNA) Earnings and Revenue Records

Verona Pharma Plc ADR’s EPS decrease for this current 12-month fiscal period is -188.89% and is forecasted to reach -0.20 in the upcoming year.

Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators

Let’s observe the current performance indicators for Verona Pharma Plc ADR (VRNA). It’s Quick Ratio in the last reported quarter now stands at 8.61. The Stock has managed to achieve an average true range (ATR) of 1.65.

In the same vein, VRNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.56, a figure that is expected to reach -0.06 in the next quarter, and analysts are predicting that it will be -0.20 at the market close of one year from today.

Technical Analysis of Verona Pharma Plc ADR (VRNA)

Through scrutinizing the latest numbers posted by the [Verona Pharma Plc ADR, VRNA], it can be observed that its last 5-days Average volume of 1.03 million was better the volume of 0.9 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 65.47% While, its Average True Range was 1.72.

Raw Stochastic average of Verona Pharma Plc ADR (VRNA) in the period of the previous 100 days is set at 89.68%, which indicates a major rise in contrast to 62.94% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 35.17% that was lower than 65.07% volatility it exhibited in the past 100-days period.